Saturday 17 October 2026
Export RNAC’s income statement to Excel — free account
Cartesian Therapeutics, Inc.
RNAC Healthcare Biotechnology
Cartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.9%, EPS fell 7.84% and free cash flow fell 6.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.27
0.31
−4.71%
Follow RNAC
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.10 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 2 | 3 | 5 | 4 | 4 | 5 | 2 | 4 | 2 |
P/S ratio |
22.42 | 1,009.46 | 287.43 | 16.18 | 13.17 | 4.38 | 1.50 | 3.91 | 7.95 | 66.95 |
Altman Z-Score |
0.56 | (1.61) | (12.73) | (4.94) | (2.95) | (1.16) | (0.13) | (3.44) | (1.52) | (4.74) |
Altman Z″-Score (non-manufacturers) |
(1.09) | (4.44) | (29.46) | (10.37) | (7.62) | (5.83) | (0.94) | (8.32) | (2.96) | (10.08) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 8.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
122.25 | (16.50) | (4.67) | (8.41) | (42.25) | (11.84) | (14.04) | (4.36) | (44.19) | (10.57) |
Beneish M-Score |
(4.01) | (4.11) | — | — | (3.23) | 1.73 | (0.25) | (1.43) | (3.09) | 8.92 |
P/B ratio |
3.30 | 4.03 | 0.00 | 12.90 | 0.00 | 16.53 | 1.77 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
3.30 | 4.03 | 0.00 | 12.90 | 0.00 | 16.53 | 1.77 | 0.00 | 0.00 | 0.00 |
EV/Sales |
13.49 | 666.54 | 312.53 | 8.70 | 8.31 | 3.17 | 0.52 | 1.87 | 3.11 | 30.80 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.75 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(5.52) | (2.65) | (1.09) | (1.13) | 5.54 | (4.47) | (1.83) | (0.95) | (5.10) | (1.17) |
EV/FCF |
(5.36) | (2.62) | (1.08) | (1.13) | 5.66 | (4.39) | (1.77) | (0.95) | (3.73) | (1.09) |
Quick Ratio |
6.16 | 8.81 | 1.06 | 2.72 | 1.79 | 1.91 | 5.76 | 1.26 | 9.29 | 8.45 |
Current Ratio |
6.33 | 8.99 | 1.20 | 2.77 | 1.86 | 2.00 | 5.91 | 1.33 | 9.43 | 8.65 |
Net Debt/EBITDA |
2.14 | 1.20 | 0.25 | 1.37 | 2.01 | 31.15 | (7.01) | 0.90 | 4.97 | 0.89 |
Debt/Assets |
13.49% | 20.81% | 48.08% | 18.99% | 15.54% | 16.03% | 15.83% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.22 | 0.41 | (3.95) | 2.25 | (1.43) | 1.14 | 0.28 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.12 | 0.00 | 0.01 | 0.09 | 0.13 | 0.52 | 0.68 | 0.11 | 0.11 | 0.01 |
Operating CF/Net income |
0.55 | 0.80 | 0.91 | 0.93 | (0.51) | 2.35 | (0.89) | 0.23 | 0.31 | 0.57 |
Capex/Depreciation |
(0.59) | (0.74) | (0.90) | 0.13 | (1.01) | (0.83) | (1.32) | (0.27) | (7.60) | (1.84) |
Interest Coverage |
(27.67) | (52.89) | (43.52) | (34.53) | (36.52) | (1.62) | 4.80 | (30.50) | — | — |
| 117.69% | (122.36%) | (281.64%) | (3,716.01%) | 1,433.57% | (1,137.85%) | 60.82% | 126.87% | 34.64% | 195.88% | |
| (54.81%) | (68.61%) | (89.76%) | (76.85%) | (51.98%) | (15.79%) | 21.72% | (93.31%) | (20.92%) | (35.63%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(48.18%) | (72.74%) | (721.23%) | (87.93%) | (96.75%) | (34.56%) | 28.11% | (891.93%) | (38.03%) | (102.99%) |
Average Days of Receivables |
9.71 | 111.09 | 0.00 | 273.33 | 158.87 | 42.53 | 32.15 | 124.24 | 8.18 | 145.50 |
Research and Development Expense of Revenue |
367.46% | 21,818.84% | 5,280.95% | 640.15% | 328.40% | 80.79% | 65.34% | 274.03% | 115.91% | 2,074.87% |
Selling, General and Administrative Expense of Revenue |
161.46% | 9,094.69% | 2,019.71% | 245.45% | 113.95% | 24.61% | 21.54% | 155.55% | 77.42% | 1,125.06% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.11 | 0.16 |
Share Based Compensation of Revenue |
25.37% | 1,971.50% | 632.78% | 77.30% | 32.67% | 9.07% | 10.10% | 86.62% | 16.91% | 376.15% |
Graham Net Nets |
0.29 | 0.24 | (0.13) | 0.05 | (0.10) | 0.02 | 0.46 | (3.48) | (0.73) | (1.57) |
Graham Number |
0.00 | 0.00 | 119.53 | 0.00 | 49.91 | 0.00 | 60.68 | 308.84 | 6.48 | 23.64 |
Earnings Yield |
(42.79%) | (31.38%) | (109.51%) | (51.31%) | (22.80%) | (7.37%) | 24.37% | (253.40%) | (26.45%) | (70.87%) |
Free Cash Flow Yield |
(11.23%) | (25.25%) | (100.75%) | (47.42%) | 11.14% | (16.51%) | (19.74%) | (50.56%) | (10.48%) | (42.40%) |
Revenue per Share |
23.13 | 0.30 | 1.21 | 4.40 | 4.92 | 22.35 | 22.98 | 5.03 | 2.25 | 0.11 |
Operating CF per Share |
(56.53) | (76.49) | (79.35) | (33.91) | 10.35 | (15.86) | (6.56) | (9.90) | (1.37) | (2.85) |
Capex per Share |
(1.67) | (1.07) | (1.05) | 0.05 | (0.22) | (0.28) | (0.25) | (0.04) | (0.51) | (0.21) |
Free Cash Flow per Share |
(58.20) | (77.56) | (80.40) | (33.86) | 10.13 | (16.15) | (6.81) | (9.93) | (1.88) | (3.06) |
Cash per Share |
240.97 | 142.07 | 50.17 | 59.45 | 41.15 | 33.64 | 27.92 | 14.88 | 12.31 | 4.82 |
Shareholders Equity per Share |
157.24 | 76.17 | (7.27) | 5.54 | (5.34) | 5.92 | 19.46 | (27.01) | (0.39) | (4.86) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
157.24 | 76.17 | (7.27) | 5.54 | (5.34) | 5.92 | 19.46 | (27.01) | (0.39) | (4.86) |
Free Cash Flow |
(20.34) | (52.75) | (59.95) | (51.36) | 34.14 | (61.47) | (32.83) | (51.37) | (32.42) | (79.39) |
Working Capital |
73.11 | 87.71 | 6.93 | 61.72 | 69.80 | 72.19 | 123.06 | 22.52 | 193.65 | 114.34 |
Capital Expenditures |
(0.58) | (0.73) | (0.78) | 0.08 | (0.74) | (1.08) | (1.20) | (0.21) | (8.74) | (5.45) |
Net Current Asset Value |
52.47 | 49.39 | (7.82) | 5.50 | (32.10) | 7.08 | 76.08 | (353.95) | (225.20) | (293.37) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.99 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.07 | 3.52 | 0.87 | (0.01) | 0.04 | 0.01 | 0.01 | 0.01 | 0.22 | 1.95 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.44 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.49 | 0.47 | 0.41 | 0.47 | 0.53 | 0.61 | 0.33 | 0.36 | 0.12 | 0.24 |
Cash ROIC |
(13.45%) | (31.12%) | (112.32%) | (43.72%) | 23.32% | (34.88%) | (12.89%) | 81.90% | (15.75%) | 7,211.17% |
Accounts Receivable Turnover |
15.56 | 1.49 | 0.00 | 2.64 | 2.72 | 9.93 | 11.26 | 2.79 | 8.00 | 2.82 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
0.52 | 0.14 | — | 2.53 | 6.11 | 8.57 | 9.84 | 9.30 | 4.86 | 0.99 |
Average Payables |
3.03 | 2.74 | 1.35 | 0.80 | 0.47 | 0.33 | 0.27 | 1.73 | 1.72 | 0.79 |
Average Assets |
66.06 | 95.20 | 72.79 | 72.03 | 132.50 | 162.66 | 162.88 | 235.47 | 370.04 | 365.72 |
Average Common Equity |
(30.77) | 53.39 | 23.20 | 1.49 | (4.80) | 2.26 | 58.17 | (173.18) | (223.49) | (66.52) |
Columns are period end dates